Viral Clearance and Inflammatory Response Patterns in Adults Hospitalized for Pandemic 2009 Influenza A(H1N1) Virus Pneumonia

Abstract

Background

Little is known about the virological and inflammatory responses of severe pandemic 2009 influenza A(H1N1) virus pneumonia during antiviral treatment.

Methods

In a prospective observational study, we recruited consecutive adults hospitalized with confirmed pandemic 2009 H1N1 infection during a 16-week period. Nasopharyngeal aspirate and non-respiratory samples (blood, stool and urine) were collected at presentation, and serial nasopharyngeal flocked swabs (NPFS) and tracheal aspirates (TA) were collected after initiating oseltamivir treatment for quantitative viral RNA assay, using real-time reverse transcriptase-PCR. Serial plasma samples were collected for cytokine/chemokine assay using cytometric bead array. Patients with severe pneumonia (lung infiltrates and hypoxaemia) were compared to those with milder illnesses.

Results

A total of 66 patients were studied (mean age 43 ±20 years); 28 (42%) developed severe pneumonia, of whom 10 (15%) required intubation. Severe pneumonia was associated with older age, dyspnoea, delayed presentation >2 days from onset, extrapulmonary virus detection (13–28%) and higher viral concentration despite late-presentation (multiple linear regression, β=0.94, 95% confidence interval 0.15–1.74; P=0.02). Patients with severe pneumonia exhibited slow viral clearance with oseltamivir treatment, particularly in the lower respiratory tract (median [interquartile range] durations of RNA positivity after antiviral initiation were NPFS 6.0 days [3.0–8.0], TA 11.0 days [7.8–14.3] versus milder illness group NPFS of 2.0 days [1.0–3.0] days; P<0.01). High viral load in lower respiratory tract despite upper-tract RNA negativity and viral rebound after stopping treatment were noted in some patients. H275Y mutation was absent. High plasma levels of interleukin (IL)-6, CXCL-8 (IL-8), CCL2 (monocyte chemoattractant protein-1) and soluble tumour necrosis factor receptor-1 were observed, which correlated with the extent and progression of pneumonia in hospital.

Conclusions

In severe 2009 H1N1 pneumonia, viral clearance is slow with treatment, particularly in the lower respiratory tract. A more sustained antiviral regime appears warranted.

References

World Health Organization. Pandemic (H1N1) 2009 – update 94. (Accessed 31 May 2010.) Available from http://www.who.int/csr/don/2010_04_01/en/index.html.

Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med 2010; 362: 1708–1719.

Echevarría-Zuno

, Mejía-Aranguré

J.M.

, Mar-Obeso

A.J.

Infection and death from influenza A H1N1 virus in Mexico: a retrospective analysis. Lancet 2009; 374: 2072–2079.

US Centers for Disease Control and Prevention. H1N1 Flu. Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April 2009 – April 10, 2010. (Accessed 31 May 2010.) Available from http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.

Jain

, Kamimoto

, Bramley

A.M.

Hospitalized patients with 2009 H1N1 influenza in the United States, April–June 2009. N Engl J Med 2009; 361: 1935–1944.

Dominguez-Cherit

, Lapinsky

S.E.

, Macias

A.E.

Critically ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 2009; 302: 1880–1887.

Kumar

, Zarychanski

, Pinto

Critically ill patients with 2009 influenza A(H1N1) infection in Canada. JAMA 2009; 302: 1872–1879.

Louie

J.K.

, Acosta

, Winter

Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009; 302: 1896–1902.

The ANZIC Influenza Investigators. Critical care services and 2009 H1N1 influenza in Australia and New Zealand. N Engl J Med 2009; 361: 1925–1934.

10.

Rello

, Rodriguez

, Ibanez

Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care 2009; 13: R148.

11.

Zarychanski

, Stuart

T.L.

, Kumar

Correlates of severe disease in patients with 2009 pandemic influenza (H1N1) virus infection. CMAJ 2010; 182: 257–264.

12.

Campbell

, Rodin

, Kropp

Risk of severe outcomes among patients admitted to hospital with pandemic (H1N1) influenza. CMAJ 2010; 182: 349–355.

13.

World Health Organization. Clinical management of human infection with pandemic (H1N1) 2009. (Updated November 2009. Accessed 31 May 2010.) Available from http://www.who.int/csr/resources/publications/swineflu/clinical_management_h1n1.pdf.

14.

Harper

S.A.

, Bradley

J.S.

, Englund

J.A.

Seasonal influenza in adults and children – diagnosis, treatment, chemoprophylaxis, and institutional outbreak management: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 1003–1032.

15.

Lee

, Choi

K.W.

, Chan

P.K.

Outcomes of adults hospitalised with severe influenza. Thorax 2010; 65: 510–515.

16.

Lee

, Chan

P.K.S.

, Choi

K.W.

Factors associated with early hospital discharge of adult influenza patients. Antivir Ther 2007; 12: 501–508.

17.

Lee

, Chan

P.K.

, Hui

D.S.

Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis 2009; 200: 492–500.

18.

Lee

, Wong

C.K.

, Chan

P.K.

Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection. Clin Infect Dis 2007; 45: 723–731.

19.

Lam

W.Y.

, Leung

T.F.

, Lee

Development and comparison of molecular assays for the rapid detection of the pandemic influenza A (H1N1) 2009 virus. J Med Virol 2010; 82: 675–683.

20.

Hospital Authority, Hong Kong SAR. Clinical guidelines and protocols by HAHO. (Accessed 1 December 2009.) Available from http://www.ha.org.hk/visitor/ha_visitor_index.asp?Parent_ID=138537&Content_ID=138667.

21.

Chan

M.C.

, Lee

, Chan

P.K.

, Leung

T.F.

, Sung

J.J.

Fecal detection of influenza A virus in patients with concurrent respiratory and gastrointestinal symptoms. J Clin Virol 2009; 45: 208–211.

22.

Ngai

K.L.

, Lam

W.Y.

, Lee

, Leung

T.F.

, Hui

D.S.

, Chan

P.K.

Allele-specific conventional reverse-transcription polymerase chain reaction as a screening assay for discriminating influenza a H1N1 (H275Y) oseltamivir-resistant and wild-type viruses. J Med Virol 2010; 82: 1295–1298.

23.

Wong

K.T.

, Antonio

G.E.

, Hui

D.S.

Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. Radiology 2003; 228: 401–406.

24.

Hancock

, Veguilla

, Lu

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361: 1945–1952.

25.

Gras

, Kedzierski

, Valkenburg

S.A.

Cross-reactive CD8⁺ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses. Proc Natl Acad Sci U S A 2010; 107: 12599–12604.

26.

Cao

, Li

X.W.

, Mao

Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med 2009; 361: 2507–2517.

27.

Witkop

C.T.

, Duffy

M.R.

, Macias

E.A.

Novel influenza A (H1N1) outbreak at the US Air Force Academy: epidemiology and viral shedding duration. Am J Prev Med 2010; 38: 121–126.

28.

De Serres

, Rouleau

, Hamelin

M.E.

Contagious period for pandemic (H1N1) 2009. Emerg Infect Dis 2010; 16: 783–788.

29.

Ling

L.M.

, Chow

A.L.

, Lye

D.C.

Effects of early oseltamivir therapy on viral shedding in 2009 pandemic influenza A (H1N1) virus infection. Clin Infect Dis 2010; 50: 963–969.

30.

Munster

V.J.

, de Wit

, van den Brand

J.M.

Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science 2009; 325: 481–483.

31.

Maines

T.R.

, Jayaraman

, Belser

J.A.

Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science 2009; 325: 484–487.

32.

Chan

M.C.

, Chan

R.W.

, Yu

W.C.

Tropism and innate host responses of the 2009 pandemic H1N1 influenza virus in ex vivo and in vitro cultures of human conjunctiva and respiratory tract. Am J Pathol 2010; 176: 1828–1840.

33.

Itoh

, Shinya

, Kiso

In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460: 1021–1025.

34.

Leekha

, Zitterkopf

N.L.

, Espy

M.J.

, Smith

T.F.

, Thompson

R.L.

, Sampathkumar

Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007; 28: 1071–1076.

35.

Bermejo-Martin

J.F.

, Ortiz de Lejarazu

, Pumarola

Th1 and Th17 hypercytokinemia as early host response signature in severe pandemic influenza. Crit Care 2009; 13: R201.

36.

K.K.

, Hung

I.F.

, Li

I.W.

Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis 2010; 50: 850–859.

37.

I.W.

, Hung

I.F.

, To

K.K.

The natural viral load profile of patients with pandemic 2009 influenza A(H1N1) and the effect of oseltamivir treatment. Chest 2010; 137: 759–768.

38.

Yeh

, Luo

R.F.

, Dyner

Preferential lower respiratory tract infection in swine-origin 2009 A(H1N1) influenza. Clin Infect Dis 2010; 50: 391–394.

39.

Fleury

, Burrel

, Weber

C.B.

Prolonged shedding of influenza A(H1N1) virus: two case reports from France. Euro Surveill 2009; 14: 19434.

40.

World Health Organization. Infection prevention and control in health care for confirmed or suspected cases of pandemic (H1N1) 2009 and influenza-like illnesses. (Updated 16 December 2009. Accessed 17 June 2010.) Available from http://www.who.int/csr/resources/publications/swineflu/swineinfinficont/en/index.html.

41.

de Jong

M.D.

, Simmons

C.P.

, Thanh

T.T.

Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006; 12: 1203–1207.

42.

Hayden

Developing new antiviral agents for influenza treatment: what does the future hold?

Clin Infect Dis 2009; 48 Suppl 1: S3–S13.

43.

Birnkrant

, Cox

The emergency use authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med 2009; 361: 2204–2207.

44.

Tramontana

A.R.

, George

, Hurt

A.C.

Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16: 1068–1075.